#391
|
||||
|
||||
ß âñå ñ òîé æå òåìîé ïðî ìóêîâèñöèäîç. Íàâîæó çàâåðøàþùèé ãëÿíåö.
Restricted peer support due to infection avoidance ×òî áû ýòî ìîãëî çíà÷èòü? (íå ìîãó ïîíÿòü çíà÷åíèå ñëîâà peer) |
#392
|
|||
|
|||
Òàê äóìàþ, ÷òî "âî èçáåæàíèå èíôåêöèé/èíôèöèðîâàíèÿ, ñëåäóåò îãðàíè÷èòü ïîñåùåíèÿ äðóçåé (ãðóïïû ïîääåðæêè)".
|
#393
|
||||
|
||||
Ýòî îïÿòü ÿ
×òî-òî ó ìåíÿ ñî ñòàòèñòè÷åñêèìè òåðìèíàìè ïðîáëåìà To provide 90% power to detect superiority if the real treatment difference was 4%, it was estimated that 621 patients (207 in each treatment arm) would be required in the intention-to-treat population. è âîò åùå percent change from baseline in ...(äàëåå èäåò ïåðå÷èñëåíèå ðÿäà ëàáîðàòîðíûõ ïîêàçàòåëåé) averaged over 6 to 12 weeks and at 2, 6, and 12 weeks çàòðóäíåíèÿ â ïåðåâîäå âûäåëåííîãî ôðàãìåíòà |
#394
|
||||
|
||||
To provide 90% power to detect superiority if the real treatment difference was 4%, it was estimated that 621 patients (207 in each treatment arm) would be required in the intention-to-treat population.
×òîáû ñîçäàòü 90% (ñòàòèñòè÷åñêóþ) ìîùíîñòü/ñèëó äëÿ îáíàðóæåíèÿ ïðåâîñõîäñòâà (îäíîãî ëå÷åíèÿ íàä äðóãèì) â ñëó÷àå, åñëè ðàçíèöà â ëå÷åíèè áóäåò áîëåå 4 %, áûëî ïîäñ÷èòàíî, ÷òî ïîòðåáóåòñÿ âîâëå÷ü 621 ïàöèåíòîâ (ïî 207 â êàæäóþ ëå÷. ïîäãðóïïó) äëÿ ïðîâåäåíèÿ êëèíè÷åñêîãî èññëåäîâàíèÿ â êàòåãîðèè "intention-to-treat"
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#395
|
||||
|
||||
percent change from baseline in ...(äàëåå èäåò ïåðå÷èñëåíèå ðÿäà ëàáîðàòîðíûõ ïîêàçàòåëåé) averaged over 6 to 12 weeks and at 2, 6, and 12 weeks
èçìåíåíèå ðàçíèöû (ëàá. ïîêàçàòåëÿ) â ïðîöåíòàõ ìåæäó ñðåäíèìè öèôðàìè, ïîëó÷åííûìè â 6 è 12 íåäåëü, è èñõîäíûìè, à òàêæå ïîëó÷åííûìè â 2, 6 è 12 íåäåëü: äåëüòà = ((ïîêàçàòåëü â 6 íåäåëü + ïîêàçàòåëü â 12 íåäåëü)/2 - èñõîäíûé ïîêàçàòåëü)õ100%
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#396
|
|||
|
|||
Äîáðîãî äíÿ âñåì!
Âîò, î÷åðåäíîé ðàç ñïîòûêàþñü ñ óäîáîâàðèìûì èçëîæåíèåì: "at the major breakpoint region and at minor cluster region breakpoints" |
#397
|
||||
|
||||
"íà ãëàâíûõ è âòîðîñòåïåííûõ ïîëîìêàõ ãåíà BCR" (àááðåâèàòóðû M-BCR è m-BCR ñîîòâåòñòâåííî, îòâå÷àþùèå çà íàëè÷èå/âûÿâëåíèå ôèëàäåëüôèéñêîé õðîìîñîìû â äèàãíîñòèêå ëåéêåìèé, áîëüøèå ïîëîìêè õàðàêòåðíû äëÿ ÕÌË, à ìàëûå âûÿâëÿþò ïðè Ôè-ïîëîæèòåëüíîé ÎËË)
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#398
|
|||
|
|||
Âûäåëåíûé ôðàãìåíò âûçâàë çàòðóäíåíèÿ.
There are currently no prospective data reporting the effect of mTOR inhibitors in this upfront setting and retrospective analysis in the poor-risk population failed to demonstrate a clear advantage for nephrectomy with temsirolimus [5]. This questions the role of nephrectomy here; however, prospective randomised trials are required to obtain quality data. Ñòàâèò ïîä âîïðîñ ðîëü/çíà÷åíèå âûïîëíåíèÿ íåôðýêòîìèè - ãäå? (ñòàòüÿ ïðî ñóíèòèíèá) putting these results in context |
#399
|
||||
|
||||
Ïî ñìûñëó, âåðîÿòíî èìååòñÿ â âèäó ôàêò, ÷òî íåîáõîäèìîñòü âûïîëíåíèÿ íåôðýêòîìèè â äîïîëíåíèè ê Òåìñèðîëèìóñó íåäîñòàòî÷íî äîêàçàíà (âåðîÿòíî ðå÷ü î ãåíåðàëèçîâàííîì ðàêå ïî÷êè). Åñëè íå îøèáàþñü, ðàíåå ñ÷èòàëîñü, ÷òî ïðè òåðàïèè èíãèáèòîðàìè ïðîòåàç, ñîõðàíåííàÿ ïî÷êà óõóäøàåò ïðîãíîç.
|
#400
|
|||
|
|||
Óãó, âðîäå ïî ñìûñëó/ëîãèêå äîëæíî áûòü "ïðè òîì-òî" èëè "â òàêîé-òî ñèòóàöèè"... âðîäå...
However, sunitinib is widely used and recommend here. Âîò è õåðå ïîéìåøü, êàê ïðàâèëüíî, â Âåëèêîáðèòàíèè èëè ïðè ðàêå ïî÷êè. Òàì âñÿ ñòàòüÿ ïðîòî ïîäàðîê - êèøèò îáîðîòàìè ïîäîáíî ýòèì. Ê ïðèìåðó became ineligible (ïðè îòñóòñòâèè óïîìèíàíèÿ î êðèòåðèÿõ âêëþ÷åíèÿ) - îçíà÷àåò "íèêòî íå ñòàë íåîïåðàáåëüíûì" , õîòÿ ïî êàêèì êðèòåðèÿì ýòî îïðåäåëÿëîñü, åñëè îïåðèðîâàëèñü íå âñå - ? Ïðè òîì, ÷òî äàëåå ïèøóò "inoperable": majority of patients obtained some tumour shrinkage and none became inoperable, which is reassuring. ×òî ýòî ìîæåò "ïîäòâåðæäàòü"? Èëè ýòî "îáíàäåæèâàåò"?  îáùåì, ïëþþñü òðåòèé äåíü |
#401
|
||||
|
||||
Óâàæàåìûå êîëëåãè, çàñòðÿëà íà ôðàçå
TC: HDL-C ratio (if an HDL cholesterol measurement is not available assume it is 1.0) Èíäåêñ TC: HDL-C èñïîëüçóþò ïðè óñëîâèè, åñëè èçìåðåíèå HDL ??? Ïîìîãèòå, ïîæàëóéñòà. |
#402
|
||||
|
||||
Äîøëî ÷óòü ïîçæå, ïîñëå ïîÿñíåíèé â òåêñòå.
"Åñëè èçìåðåíèå HDL íåâîçìîæíî, îí ïðèíèìàåòñÿ ðàâíûì 1,0" |
#403
|
|||
|
|||
Implicit in this discussion is that a suitable gold standard has been established for purposes of determining true status for each specimen
Âðîäå past perfect îçíà÷àåò, ÷òî òåñò óæå áûë ñîçäàí/ðàçðàáîòàí/óòâåðæäåí. Íå ìîãó ïîíÿòü ïðàâèëüíûé ñìûñë ïåðâîé ÷àñòè ïðåäëîæåíèÿ....... Participation in external proficiency testing program with at least two testing events (mailings)/year äèñòàíöèîííîå òåñòèðîâàíèå? |
#404
|
||||
|
||||
"Î÷åíü áëèçêîå îòíîøåíèå ê ýòîé äèñêóññèè èìååò òîò ôàêò, ÷òî ïîäõîäÿùèé çîëîòîé ñòàíäàðò áûë ðàçðàáîòàí äëÿ öåëåé..."
"implicit" meaning: 2) Essentially or very closely connected with --- íåêîòîðûå òåñòû ìîãóò ïðèñûëàòüñÿ ïî ïî÷òå (÷òî-òî âðîäå ñèòóàöèîííûõ çàäà÷), ñïåöèàëèñò ïðèíèìàåò ðåøåíèå è îòïðàâëÿåò ñâîé îòâåò, çàòåì ïîëó÷àåò îòâåò îò ñîçäàòåëÿ ïðîãðàììû è ñðàâíèâàåò ñî ñâîèì - ó íàñ â ëàáîðàòîðèè íàïðèìåð åñòü ïîäîáíîå òåñòèðîâàíèå (íåñê. ðàç â ãîä) íà ïðàâèëüíóþ èíòåðïðåòàöèþ òåñòîâ àãðåãàöèè òðîìáîöèòîâ ó ãèïîòåòè÷åñêîãî áîëüíîãî...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#405
|
|||
|
|||
Äóæå Âàì âäÿ÷í³, äÿäüêó! ;-)
|